SOLU-CORTEF FOR INJECTION 100 mgvial

Nchi: Singapoo

Lugha: Kiingereza

Chanzo: HSA (Health Sciences Authority)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
26-09-2022
Tabia za bidhaa Tabia za bidhaa (SPC)
28-09-2021

Viambatanisho vya kazi:

HYDROCORTISONE SODIUM SUCCINATE

Inapatikana kutoka:

PFIZER PRIVATE LIMITED

ATC kanuni:

H02AB09

Kipimo:

100 mg/vial

Dawa fomu:

INJECTION, POWDER, FOR SOLUTION

Tungo:

HYDROCORTISONE SODIUM SUCCINATE 100 mg/vial

Njia ya uendeshaji:

INTRAVENOUS, INTRAMUSCULAR

Dawa ya aina:

Prescription Only

Viwandani na:

PFIZER MANUFACTURING BELGIUM NV

Idhini hali ya:

ACTIVE

Idhini ya tarehe:

1990-06-26

Taarifa za kipeperushi

                                SOLU-CORTEF
TABLE OF CONTENT
_Please click on either of the following links to access the required
information: _
PRESCRIBING INFORMATION
PATIENT INFORMATION LEAFLET
Page
1
of
17
1. NAME OF THE MEDICINAL PRODUCT
SOLU-CORTEF™ For Injection 100 mg/vial.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Hydrocortisone sodium succinate equivalent to hydrocortisone 100 mg.
3. PHARMACEUTICAL FORM
White, lyophilized powder for solution for injection.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
1. ENDOCRINE DISORDERS
Primary or secondary adrenocortical insufficiency (hydrocortisone or
cortisone is the drug of
choice; synthetic analogues may be used in conjunction with
mineralocorticoids where
applicable; in infancy mineralocorticoid supplementation is of
particular importance)
Acute adrenocortical insufficiency (hydrocortisone or cortisone is the
drug of choice;
mineralocorticoid supplementation may be necessary, particularly when
synthetic analogues
are used)
Pre-operatively, and in the event of serious trauma or illness, in
patients with known adrenal
insufficiency or when adrenocortical reserve is doubtful
Shock unresponsive to conventional therapy if adrenocortical
insufficiency exists or is
suspected
Congenital adrenal hyperplasia
Non-suppurative thyroiditis
Hypercalcemia associated with cancer
2. NON-ENDOCRINE DISORDERS
Rheumatic Disorders - As adjunctive therapy for short-term
administration (to tide the patient
over an acute episode or exacerbation) in:
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis
(selected cases may require low-
dose maintenance therapy)
Epicondylitis
Acute non-specific tenosynovitis
Acute gouty arthritis
Psoriatic arthritis
Ankylosing spondylitis
Acute and subacute bursitis
Page
2
of
17
Collagen Diseases - During an exacerbation or as maintenance therapy
in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
Dermatologic Diseases
Pemphigus
Bullous dermatiti
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1. NAME OF THE MEDICINAL PRODUCT
SOLU-CORTEF™ For Injection 100 mg/vial.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Hydrocortisone sodium succinate equivalent to hydrocortisone 100 mg.
3. PHARMACEUTICAL FORM
White, lyophilized powder for solution for injection.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
1. ENDOCRINE DISORDERS
Primary or secondary adrenocortical insufficiency (hydrocortisone or
cortisone is the drug of
choice; synthetic analogues may be used in conjunction with
mineralocorticoids where
applicable; in infancy mineralocorticoid supplementation is of
particular importance)
Acute adrenocortical insufficiency (hydrocortisone or cortisone is the
drug of choice;
mineralocorticoid supplementation may be necessary, particularly when
synthetic analogues
are used)
Pre-operatively, and in the event of serious trauma or illness, in
patients with known adrenal
insufficiency or when adrenocortical reserve is doubtful
Shock unresponsive to conventional therapy if adrenocortical
insufficiency exists or is
suspected
Congenital adrenal hyperplasia
Non-suppurative thyroiditis
Hypercalcemia associated with cancer
2. NON-ENDOCRINE DISORDERS
Rheumatic Disorders - As adjunctive therapy for short-term
administration (to tide the patient
over an acute episode or exacerbation) in:
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis
(selected cases may require low-
dose maintenance therapy)
Epicondylitis
Acute non-specific tenosynovitis
Acute gouty arthritis
Psoriatic arthritis
Ankylosing spondylitis
Acute and subacute bursitis
Collagen Diseases - During an exacerbation or as maintenance therapy
in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
Dermatologic Diseases
Pemphigus
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Exfoliative dermatitis
Mycosis fungoides
Severe psoriasis
Severe seborrheic dermatitis
Allergic States - Control of severe
                                
                                Soma hati kamili